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Purpose: To evaluate the long-term efficacy of infliximab in patients with refractory Behçet’s 
disease (BD)-associated and idiopathic posterior uveitis (PU).
Methods: Single center, prospective, 6-year duration, follow-up study on 50 consecutive 
patients (20 [40%] males and 30 [60%] females with a mean age of 37.5 ± 12.3 years) with 
refractory BD-associated PU (36 patients) and idiopathic PU (14 patients) who had failed at 
least one immunosuppressive drug. At baseline, patients received prednisone 1 mg/kg/day with 
rapid tapering and infliximab infusions (5 mg/kg) at weeks 0, 2, 6, and every 8 weeks thereafter. 
Nonresponders after the third infusion withdrew from the study. Primary outcome measures were 
visual acuity (VA) value improvement compared to baseline. Secondary outcome measures were 
proportion of patients with VA improvement from baseline; proportion of patients achieving 
disease remission; number of PU flare-ups; and incidence of adverse events.
Results: At the final follow-up, mean right and left eye VA respectively increased from 
0.57 ± 0.31 at baseline to 0.68 ± 0.33 (P = 0.048) and from 0.67 ± 0.28 to 0.76 ± 0.27 
(P = 0.047). None of the patients had VA worsening and new onset ocular complications. 
A complete response of PU was recorded in 34/50 (68%) patients and partial response in 11/50 
(22%). Five patients were nonresponders and withdrew from the study after the third infusion. 
A significant reduction of ocular attacks and of the proportion of patients with cystoid macular 
edema was observed. No differences in infliximab efficacy was recorded between patients with 
BD-associated and idiopathic PU. No serious adverse events occurred. The mean follow-up 
duration was 36.8 months.
Conclusion: Long-term infliximab therapy was equally effective and safe with a significant 
VA gain in refractory BD-associated and idiopathic PU.
Keywords: Behçet’s disease, idiopathic posterior uveitis, infliximab, posterior uveitis, visual 
acuity
Introduction
Noninfectious posterior uveitis (PU) are immune-related, sight-threatening 
  inflammatory conditions that account for 22% to 38% of all cases of uveitis seen in 
tertiary care centers.1–4
According to the Standardization of Uveitis Nomenclature (SUN) working group clas-
sification, the inflammatory process of PU may involve the choroid and the retina causing 
variable clinical patterns such as focal, multifocal, diffuse choroiditis,   chorioretinitis, 
retinochoroiditis, retinitis, or neuroretinitis.5 As reported in a recent systematic review 
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of the literature,6 PU are mainly caused by Behçet’s disease 
(BD), serpiginous choroiditis and sarcoidosis, otherwise PU 
remain idiopathic in around 35% of cases.
BD-associated PU and idiopathic PU, with or without 
associated retinal vasculitis, share a relapsing and remitting 
clinical course with frequent occurrence of ocular complica-
tions such as cataract, cystoid macular edema, retinal detach-
ment, papillitis, and intraretinal/subretinal hemorrhages, 
with progressive worsening of visual function leading to 
blindness in up to 25% of patients.7 Over a 30-year period, 
a trend toward improvement of prognosis has been recorded 
by treating the disease with high-dose corticosteroids (CS) 
combined with traditional immunosuppressive drugs includ-
ing methotrexate, cyclosporine (CsA), azathioprine (AZA), 
and cyclophosphamide.8 However, PU may be particularly 
resistant to CS and immunosuppressants with rapid progres-
sion to vision loss in 10%–25% of cases.9,10
The inflammatory process of both BD-associated and 
idiopathic PU is sustained by a Th1-mediated response with 
increased secretion of proinflammatory cytokines including 
interleukin-1, interleukin-6, and especially tumor necrosis 
factor alpha (TNFα) that has been demonstrated to play a 
pivotal role in the pathogenesis of autoimmune uveitis.11–17
Following this evidence, the efficacy of anti-TNF agents 
including infliximab (IFX) and adalimumab in patients with 
refractory BD-associated or idiopathic PU has been reported 
in recent open, short-term studies of small clinical ser ies.18
The long-term efficacy of anti-TNF therapy was 
  confirmed by our group in an open-label, 24-month, prospec-
tive, follow-up study on 12 patients with BD and refractory 
posterior uveitis receiving IFX 5 mg/kg. A complete remis-
sion after the third infusion in six patients and in nine after 
the fourth was recorded, with maintenance of remission in 
seven out of nine patients at the 24-month visit.19
The primary objective of this prospective study was to 
evaluate the efficacy of IFX therapy in terms of improvement 
in visual acuity (VA) in a cohort of consecutive patients with 
refractory idiopathic PU and BD-associated PU.
Patients and methods
Setting
The Rheumatology Unit of Prato Hospital is a secondary 
referral center which serves around 300,000 people living 
in the Prato province and the surrounding industrial areas. 
About 75% of patients are sent by their general practitioners, 
and the remaining are self-referred.
In March 2004, the Rheumatology Unit was appointed 
as the tertiary referral center for rare rheumatic diseases. 
Patients with these conditions are self-referred or sent by 
other specialists from all parts of Italy.
From January 2005 to December 2010, in collaboration 
with the Ophthalmology Department of Prato Hospital, all 
consecutive new patients with refractory PU underwent the 
same diagnostic and therapeutic schedule and all data were 
recorded in an individual computed chart.
At baseline all patients underwent the following investiga-
tions: history taking, physical examination, purified protein 
derivative (PPD) test, laboratory tests including erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), blood 
cell count with differential count, renal and liver function, 
human leukocyte antigen typing, antinuclear antibody titer, 
and serology for toxoplasma, human immunodeficiency 
virus, syphilis, lysozyme, or angiotensin-converting enzyme. 
Ophthalmologic evaluation consisted of a complete ocular 
examination including best-corrected VA (Snellen chart of 
0.1–1.0), slit-lamp biomicroscopy, tonometry and ophthal-
moscopy, optical coherence tomography (OCT), and fundus 
fluorescein angiography (FFA).
Inclusion criteria
To be enrolled, patients should have a diagnosis of idiopathic 
or BD-associated chronic PU, with or without retinal vascu-
litis, resistant to a dose of prednisone or equivalent greater 
than 10 mg/day, and at least one immunosuppressive drug 
after at least 12 months of treatment.20
The diagnosis of BD was formulated according to the 
International Study Group (ISG) criteria.21 As VA loss during 
BD flare-ups may be reversible following treatment,22 we also 
included in the study patients with active PU and unilateral 
or bilateral loss of vision of recent onset (,3 months).
Exclusion criteria
Patients with permanent blindness, with contraindications to 
IFX use, as recommended by by Centocor Ortho Biotech, 
Inc (Malvern, PA), or with a history of recent infections and 
malignancies were excluded from the study. Pregnancy and 
breastfeeding constituted additional exclusion criteria and 
contraception was recommended to all females of childbear-
ing potential.
Moreover, a careful screening for tuberculosis was made by 
detailed medical history, chest X-rays, and PPD test. Over the last 
3 years the QuantiFERON TB Gold test was also performed.
Primary end-point
The primary end-point was to assess the long-term efficacy 
of IFX therapy in patients with idiopathic or BD-associated 
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refractory PU uveitis as expressed by VA improvement 
from baseline.
Secondary end-points
Secondary end-points were to investigate the efficacy of IFX 
to reduce disease flare-up, to assess the proportion of relapse-
free subjects at the end of follow-up, and the percentage of 
patients achieving a complete or partial remission, and to 
evaluate the tolerability and safety of the treatment.
Primary outcome measure
The primary outcome measure was improvement in VA mean 
values at the end of follow-up compared to baseline.
Secondary outcome measures
Secondary outcome measures were a proportion of patients 
achieving an improvement of best-corrected right eye and 
left eye VA from baseline; proportion of patients achieving a 
complete or partial remission; timing of remission; proportion 
of relapse-free patients at the end of follow-up; number of 
ocular attacks during the treatment period; and number and 
severity of adverse events (AEs).
Definition of response
The response to therapy was calculated by a composite score 
from 0 to 7 obtained by the sum of the grade of severity of 
inflammatory infiltrate and retinal vasculitis as reported 
previously.19 The response was graded as follows:
•	 Complete remission: presence of less than 1+   cellular 
  reaction (scale 0–4), and remission of vasculitis   evaluated 
by a score (0–3) at fundus examination and FFA 
(0 = absence of vasculitis, 1 = vasculitis of   peripheral 
retinal vessels, 2 = posterior pole vasculitis, and 
3 =   vasculitis with evidence of areas of retinal necrosis). 
FFA examinations were scheduled at baseline, week 6, 
22, and 54, and yearly thereafter.
•	 Partial remission: improvement of at least 50% of 
  inflammation and retinal vasculitis scores.
•	 Absent: absence of any improvement or less than 50% 
of uveitis scores.
Treatment regimen
At baseline, all patients suspended the current immunosup-
pressive therapy, and received prednisone at the dose of 
1 mg/kg/day. In addition, all subjects received IFX 2-hour 
intravenous infusions at the dose of 5 mg/kg at weeks 0, 
2, 6, and every 8 weeks thereafter. IFX-dose escalation 
through infusion-interval shortening to 6 weeks was allowed 
in nonresponder patients or in those with partial remission 
according to the judgment of the physician. IFX infusions 
were administered for the whole duration of follow-up.
During the drug infusion and for 1 hour afterwards, 
blood pressure, pulse, and temperature were measured every 
30 minutes. Moreover, at every visit, complete blood count, 
liver, and kidney function tests were examined. Antinuclear 
antibodies (ANA) were measured at baseline and every 
6 months.
In responders, the following CS-dose tapering was 
  scheduled: 10 mg/day every 1 week until the dose of 20 mg/
day, then 5 mg/day/week until a maintenance dose of 10 mg/
day is achieved. This dose was continued for at least 2 weeks 
before attempting to further reduce the dose of 5 mg/week 
until withdrawal. In case of relapse, prednisone was increased 
by 20 mg/day. Other immunosuppressant agents and con-
comitant local CS injections were not allowed.
Patients failing to achieve at least a partial remission 
after the third infusion of IFX withdrew from the study and 
received prednisone 1 mg/kg/day and an immunosuppressant 
different from that employed before the study entry.
All patients had a complete evaluation by an ophthalmolo-
gist and a rheumatologist at baseline and over the follow-up 
visits that were scheduled 2 weeks after the third IFX infusion 
(week 8) and then every 4 months or before in case of relapse. 
The date of last visit constituted the end of follow-up.
Adverse events
At every visit, all patients were monitored for clinical and 
laboratory evidence of adverse events (AEs) defined as mild 
(transient and easily tolerated), moderate (subject discomfort 
with interruption of usual activities), or severe (incapacitat-
ing or life-threatening). The study was approved by the local 
ethical Committee and written informed consent from the 
patients was obtained.
Data statistical analysis was done using the SPSS 
statistical package (SPSS Inc, Chicago, IL). Wilcoxon’s 
matched pairs signed rank test were used to measure the 
changes from baseline of ocular inflammation and ocular 
attacks. Chi-square test for nominal variables was used to 
calculate the differences between the BD-associated and 
idiopathic PU results. Analysis of variance (ANOVA) for 
repeated measures was used to measure the VA changes. P 
values less than 0.05 were accepted as significant.
Results
Over a 6-year enrolment period, 50 patients with refractory 
PU (20 males [40%] and 30 females [60%] with a mean 
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age of 37.5 ± 12.3 years) were included into the study. 
BD-associated PU was diagnosed in 36 patients (15 males 
[42%] and 21 females [58%] females with a mean age of 
36.1 ± 10.9 years), and idiopathic PU in 14 patients (five 
males [36%] and nine females [64%] with a mean age of 
40.9 ± 15.3 years). The demographic and clinical character-
istics of the 50 patients are summarized in Table 1.
At the end of the follow up a complete response of PU 
was recorded in 34/50 (68%) patients, partial response in 
11/50 (22%), and five (10%) patients showed no improve-
ment after the third IFX infusion and withdrew from the 
study as dictated by the study protocol. Of these, three had 
BD with bilateral PU and cystoid macular edema, and two 
had idiopathic PU without macular increased thickness.
As shown in Table 2, the proportions of patients with VA 
improvement after the third IFX infusion and at the end of 
the follow up were 72% (36 patients) and 82% (41 patients), 
respectively. Mean right eye VA increased from 0.57 ± 0.31 at 
baseline to 0.63 ± 0.32 at week 8, and 0.68 ± 0.33 (P = 0.048) 
at the end of follow-up. Mean left eye VA improved from 
baseline value of 0.67 ± 0.28 to 0.74 ± 0.26 after the third 
infusion and to 0.76 ± 0.27 (P = 0.047) at the last visit. None 
of the patients had worsening VA or new onset ocular com-
plications including retinal detachments, papillitis, intra- or 
subretinal hemorrhage, intravitreal hemorrhage, and optic 
atrophy during the follow-up. A significant reduction of 
overall ocular attacks, proportion of patients with retinal 
vasculitis, and cystoid macular edema was recorded.
At the end of the follow-up, a significant improvement of 
VA from baseline value was observed either in BD-associated 
PU (right eye: 0.56 ± 0.32 vs 0.65 ± 0.33, P = 0.0005; left 
eye: 0.68 ± 0.27 vs 0.76 ± 0.27; P = 0.0004) and in idiopathic 
PU (right eye: 0.6 ± 0.31 vs 0.70 ± 0.31; P = 0.011; left eye: 
0.65 ± 0.30 vs 0.75 ± 0.29; P = 0.016). Table 3 summarizes 
the separated results in patients with idiopathic PU and in 
those with BD-associated PU. The results of efficacy of 
Table 1 Baseline demographic and concurrent clinical manifestations in 50 patients with idiopathic and Behçet’s disease-associated 
posterior uveitis
Overall Idiopathic PU BD-associated PU
Patient number 50 14 36
Male/female (no/%) 20 (40%)/30 (60%) 5 (36%)/9 (64%) 15 (42%)/21 (58%)
Age at first visit (years/mean ± SD) 37.5 ± 12.3 40.9 ± 15.3 36.1 ± 10.9
Disease duration (months/mean ± SD) 60.3 ± 64.6 51.1 ± 48.4 63.8 ± 70.2
HLA-B51+ (no/%) 26 (52%) 3 (21%) 23 (64%)
ESR (mm/h/mean ± SD) 29.5 ± 14.2 28.6 ± 13.8 29.8 ± 14.5
CRP (mg/dL/mean ± SD) 1.25 ± 1.1 0.84 ± 0.7 1.41 ± 1.2
Bilateral PU (no/%) 33 (66%) 12 (86%) 23 (64%)
Unilateral PU (no/%) 8 (16%) 1 (7%) 6 (17%)
Panuveitis (no/%) 9 (18%) 1 (7%) 7 (19%)
Retinal vasculitis (no/%) 31 (62%) 9 (64%) 22 (61%)
Ocular attacks before IFX (total no/mean ± SD) 285 (5.7 ± 5.7) 61 (4.35 ± 3.29) 224 (6.2 ± 6.3)
Previous treatment (no/%) 
CS+AZA 
CS+MTX 
CS+CSA 
CS+MTX+CSA 
CS+AZA+CSA 
CS+MTX+CSA+AZA
 
14 (28%) 
6 (12%) 
15 (30%) 
11 (22%) 
3 (6%) 
1 (2%)
 
6 (43%) 
2 (14%) 
5 (36%) 
1 (7%) 
0 (0%) 
0 (0%)
 
8 (22%) 
4 (11%) 
10 (28%) 
10 (28%) 
3 (8%) 
1 (3%)
Ocular complications (no/%) 
Cataract 
Cystoid macular edema 
Retinal detachments 
Papillitis 
Intra/subretinal hemorrhage 
Intravitreal hemorrhage 
Optic atrophy
 
9 (18%) 
19 (38%) 
4 (8%) 
8 (16%) 
5 (10%) 
3 (6%) 
5 (10%)
 
2 (14%) 
5 (36%) 
1 (7%) 
2 (14%) 
1 (7%) 
1 (7%) 
1 (7%)
 
7 (19%) 
14 (39%) 
3 (8%) 
6 (17%) 
4 (11%) 
2 (5.5%) 
4 (11%)
Visual acuity (mean ± SD) 
Right eye 
Left eye
 
0.57 ± 0.31 
0.67 ± 0.28
 
0.6 ± 0.31 
0.65 ± 0.30
 
0.56 ± 0.32 
0.68 ± 0.27
Abbreviations: AZA, azathioprine; BD, Behçet’s disease; CS, corticosteroids; CSA, cyclosporine A; IFX, infliximab; MTX, methotrexate; PU, posterior uveitis; SD, standard 
deviation.
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IFX in BD compared to idiopathic PU did not disclose any 
significant difference for all outcome measures.
After a median interval from the beginning of the treat-
ment at 8 months in seven (19%) patients with BD and in 
three (21%) patients with idiopathic PU, IFX dose escalation 
to 6-week infusion intervals was required due to uveitis flare 
up. After dose adjustment, a complete and stable uveitis 
remission was seen in eight out of ten (80%) patients and 
two out of ten (20%) achieved a partial response.
Regarding drug tolerability and safety, mild infusion 
reactions were recorded in nine (18%) patients, urinary 
  infections in six (12%), upper airways infections in 11 (16%), 
and slight liver enzymes in two (4%) with no severe adverse 
event requiring IFX interruption. ANA positivity was 
observed in ten (20%) patients during the whole period of 
follow-up, however no patients developed signs or symptoms 
of   lupus-like syndrome.
The mean follow up duration for overall PU, BD-
associated PU, and idiopathic PU was 36.8, 37.3, and 35.6, 
respectively.
Discussion
The efficacy of IFX on BD-associated and idiopathic 
  refractory PU has been reported in single case reports23–33 and 
in several clinical series (Table 4). To date, around 300 patients 
with refractory PU treated with IFX have been reported, with 
a favorable response rate ranging from 31% to 100% of cases. 
In almost all studies, the posterior eye inflammation suppres-
sion and the reduction of uveitis flare up have been adopted 
as the primary outcome measures. Two main considerations 
lead us to assume VA improvement as the primary end-point 
of the study. First, idiopathic and BD-associated PU represent 
an important cause of permanent VA reduction and blindness. 
Reduced VA and blindness are related to uncontrolled disease 
Table 2 Baseline and end of follow up results of IFX therapy in 50 patients overall with refractory PU
Clinical feature Baseline Week 8 
(After the 3rd IFX infusion)
End of follow-up P value
PU response to IFX (n/%) 
  – Complete 
  – Partial 
  – Absent
 
29 (58%) 
16 (32%) 
5 (10%)
 
34 (68%) 
11 (22%) 
5 (10%)
 
ns 
ns 
ns
Proportion of patients with VA improvement (n/%) 36 (72%) 41 (82%) ns
Relapse-free subjects (n/%) 38/50 (76%) 31 (62%) ns
Visual acuity (mean ± SD) 
  Right eye 
  Left eye
 
0.57 ± 0.31 
0.67 ± 028
 
0.63 ± 0.32 
0.74 ± 0.26
 
0.68 ± 0.33 
0.76 ± 0.27
 
0.048 
0.047
Uveitis flares up (no/mean ± SD) 285/5.70 ± 5.6 NA 38/0.76 ± 1.11 0.0001
Cystoid macular edema (no/%) 19 (38%) 14 (28%) 7 (14%) 0.008
FFA retinal vasculitis (no/%) 31 (62%) 12 (24%) 7 (14%) 0.0001
Abbreviations: FFA, fundus fluorescein angiography; IFX, infliximab; NA, not applicable; ns, not significant; PU, posterior uveitis; SD, standard deviation; VA, visual acuity.
Table 3 Results of IFX therapy divided by the diagnosis in 14 patients with idiopathic refractory PU and BD-associated PU and 
comparison between the two groups
Clinical feature Idiopathic PU (14 patients) BD-associated PU (36 patients) P 
Id. PU vs BD Baseline End of 
follow-up
P Baseline End of 
follow-up
P
PU response (N/%) 
  – Complete 
  – Partial 
  – Absent
 
9 (64%) 
3 (21%) 
2 (14%)
 
25 (69%) 
8 (22%) 
3 (8%)
ns
Proportion of patients with  
VA gain (N/%)
11 (79%) 30 (83%) ns
Visual acuity (mean ± SD) 
  RE 
  LE
 
0.6 ± 0.31 
0.65 ± 0.30
 
0.70 ± 0.31 
0.75 ± 0.29
 
0.011 
0.016
 
0.56 ± 0.32 
0.68 ± 0.27
 
0.65 ± 0.33 
0.76 ± 0.27
 
0.0005 
0.0004
ns
Uveitis flares up (no/mean ±	SD) 61 (4.35 ± 3.29) 7 (0.5 ± 0.94) 0.003 224 (6.22 ± 6.39) 31/0.86 ± 1.17 0.0001 ns
Cystoid macular edema (no/%) 5 (36%) 0 (0%) 0.0003 14 (39%) 5 (14%) 0.03 ns
FFA retinal vasculitis (no/%) 9 (64%) 1 (7%) 0.0002 22 (61%) 2 (5.5%) 0.0001 ns
Abbreviations: FFA, fundus fluorescein angiography; IFX, infliximab; NA, not applicable; ns, not significant; PU, posterior uveitis; SD, standard deviation; VA, visual acuity; 
BD, Behçet’s disease.
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duration and respectively occur in up to 69% and 20% of 
the patients after 3 years.7,8,55,56 Therefore, the primary target 
of therapy of uveitis should be to avoid VA worsening and 
blindness. This concept has been recently underlined in the 
Multicenter Uveitis Steroid Treatment (MUST) Trial study 
design.57   Second, the reproducibility of criteria for grading 
the site and the activity of intraocular inflammation is rather 
low,58 unless laser flare-cell photometry is used to quantify 
and compare the severity of uveitis.59
In our long-term, prospective study of IFX efficacy in 
refractory PU, VA improved in 41 out of 50 (82%) patients, 
with significant improvement of mean VA values at the end 
of follow up compared to baseline. Of note, in keeping with 
other studies,60 IFX was rapidly effective as demonstrated by 
the dramatic improvement of ocular inflammatory changes and 
VA after the third infusion in the majority of the patients (78%) 
and by the elevated number of patients achieving complete 
(58%) or partial remission (32%) at the same time. Moreover, 
the drug maintained its efficacy overtime even if a dose escala-
tion was required in ten out of 45 patients (22%).
The secondary outcome measures including the proportion 
of patients achieving disease remission, retinal vasculitis, and 
the frequency of uveitis relapse also improved   significantly. 
Moreover, confirming the results of other studies,61 CME 
resolved in 12 of 19 (63%) patients (P = 0.008) after a mean 
follow-up of 36.8 months.
Epidemiological data indicate that idiopathic PU account 
for at least 35% of noninfectious PU and panuveitis.6 
Similarly to BD-associated PU, idiopathic PU are immu-
nomediated conditions of the posterior segment resistant 
to combined CS and immunosuppressive drug therapy in 
20% to 30% of patients,7,12,62 and with a frequency of visual 
impairment and blindness not different from that found for 
uveitis of known etiology.55 In several clinical series of IFX 
in refractory PU, both patients with BD and idiopathic PU 
were included.35,39,41,43 The results of these studies were not 
divided by the etiology of PU with no specific information 
concerning the efficacy of IFX in patients with idiopathic PU. 
In our study, IFX was effective in patients with idiopathic PU 
with significant improvement of all outcome measures with 
respect to baseline, and there were no significant differences 
of efficacy in comparison with patients with BD.
As regards its safety profile, long-term IFX therapy was 
well-tolerated with minor infusion-related reactions occur-
ring in a minority of the patients and absence of serious 
adverse events requiring drug discontinuation.
Table 4 Reported clinical series of IFX therapy in patients with BD-associated or idiopathic refractory PU
Reference PU type Patient N° IFX dose Primary outcome  
measure
Responders  
(N/%)
Follow-up   
(months)
Sfikakis et al34 BD 5 5 mg/kg Inflammation suppression 5 (100%) 1
Joseph et al35 BD, idiopathic 5 5 mg/kg Inflammation suppression 4 (80%) 6
Sfikakis et al36 BD 15 5 mg/kg Inflammation suppression 19 (76%) 8
Ohno et al37 BD 13 5 mg/kg/10 mg/kg Flare-up frequency 10 (77%) 3
Wechsler et al38 BD 4 5 mg/kg Inflammation suppression 4 (100%) 22
Benitez-del Castillo et al39 BD, idiopathic 7 5 mg/kg Inflammation suppression 4 (57%) 36
Tugal-Tutkun et al40 BD 13 5 mg/kg Inflammation suppression 4/13 (31%) 12
Lindstedt et al41 BD, idiopathic 13 3 mg/kg Inflammation suppression 13/13 (100%) 24
Lanthier et al42 BD 4 5 mg/kg Inflammation suppression 2 (50%) 11
Suhler et al43 BD, idiopathic 23 5 mg/kg See note* 18 (78%) 2
Mushtaq B et al44 BD 3 5 mg/kg Flare-up frequency 3 (100%) 16
Abu El-Asrar AM45 BD 6 5 mg/kg Inflammation suppression 6 (100%) 36
Niccoli et al19 BD 12 5 mg/kg Inflammation suppression 7 (58%) 24
Accorinti et al46 BD 12 5 mg/kg Flare-up frequency 11 (92%) 16
Tognon et al47 BD 7 3 mg/kg 
5 mg/kg
Flare-up frequency 6 (86%) 23
Al-Rayes et al48 BD 10 5 mg/kg Flare-up frequency 7 (70%) 36
Tabbara and Al-Hemidan49 BD 10 5 mg/kg Flare-up frequency NA 30
Yamada et al50 BD 17 5 mg/kg Flare-up frequency 6
giardina et al51 BD 21 5 mg/kg Inflammation suppression 18 (86%) 12
Adán et al52 BD 4 5 mg/kg Inflammation suppression 2 (50%) 12
Yamada et al53 BD 23 5 mg/kg Flare-up frequency 10 (43%) 20
Sugita et al54 BD 20 5 mg/kg Flare-up frequency 15 (75%) 28
Notes: *Patients were considered responders if improved in at least one of four variables (visual acuity, control of intraocular inflammation, ability to taper concomitant 
medication therapy, improvement in inflammatory signs on FFA and/or OCT) and if they worsened in none.
Abbreviations: BD, Behçet’s disease; IFX, infliximab; NA, not applicable; PU, posterior uveitis; SD, standard deviation.
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A limit to our study is the open-label design that reduces 
the level of evidence. To date, IFX has been employed only 
in patients with refractory uveitis and with established, not 
reversible ocular complications in most cases. In a recent 
retrospective, 6-month study from Japan,50 IFX was sig-
nificantly more effective than CsA to reduce the frequency 
of ocular attacks in BD patients with refractory uveitis. We 
suggest randomized controlled trials to evaluate the efficacy 
of IFX compared to traditional therapy to preserve visual 
acuity in patients with autoimmune PU at onset.
In conclusion, the results of the current long-term study 
confirm that IFX has a rapid and sustained efficacy in a high 
proportion of patients with BD-associated and idiopathic 
refractory PU allowing a significant improvement of VA in 
82% of the patients, with a complete disease remission rate 
of 68% of cases. The separated data analysis indicates that 
IFX is equally effective both in patients with idiopathic PU 
and those with BD. The safety profile of the drug was good 
with no serious AEs reported.
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